As expected, gastrointestinal adverse events were more frequent in the semaglutide group
It selectively binds to GLP-1 receptors on pancreatic islet cells, enhancing insulin synthesis and suppressing glucagon secretion
Because of this, the manufacturer did not take the concept further. When SGLT-2 inhibitors like Invokana, Farxiga, and Jardiance emerged in 2013 and 2014, researchers began testing these medications in type 1 diabetes in a series of trials
Phase 3 Trial of Semaglutide in Metabolic DysfunctionAssociated Steatohepatitis, New England Journal of Medicine Consistent with previous trials, the semaglutide group also lost more body weight and had significant improvements in blood pressure, blood glucose, lipids, and inflammation compared to the placebo group
Theres no strong rationale that a higher dose would have meaningfully slowed cognitive decline
After which, theyll determine whether Semaglutide is suitable for you